Advanced uterine sarcoma; response to chemotherapy.
A 15 year retrospective study of chemotherapy response to multiple regimens employed in 78 evaluable patients with advanced uterine sarcoma was performed. Single agent activity was noted with doxorubicin, methotrexate, and cisplatin (5-11% response rate). Effective multigent regimens included cyclophosphamide, vincristine, doxorubicin, dacarbazine (CYVADIC) (23% response), cisplatin and dacarbazine (21% response) and vincristine, dactinomycin, and cyclophosphamide (VAC) (18% response). There was no difference in response rate among different histologies. More active agents or combinations are needed.
Piver
M S
MS
Dept. of Gynecologic Oncology, Roswell Park Memorial Institute, Buffalo, New York.
Rose
P G
PG
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D012189:Retrospective Studies; D012509:Sarcoma / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents